CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Humanigen Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Humanigen Inc
830 MORRIS TURNPIKE, 4TH FLOOR
Phone: (973) 200-3100p:973 200-3100 SHORT HILLS, NJ  07078  United States Fax: (302) 531-3150f:302 531-3150
This company's Plan of Liquidation went into effect on 7/12/2024
This entity represents the bankrupt estate of the former businesses (assets) of Humanigen, Inc. that were not sold to Taran Therapeutics Inc. on 2/20/2024
This company is no longer actively traded on any major stock exchange.
Business Summary
Humanigen, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing its portfolio of proprietary Humaneered anti-inflammatory immunology and immuno-oncology monoclonal antibodies. Its Humaneered technology platform is a method for converting existing antibodies (typically murine) into engineered, high-affinity human antibodies designed for therapeutic use, particularly with acute and chronic conditions. Its product candidate, lenzilumab, and its other product candidate, ifabotuzumab (iFab), are Humaneered monoclonal antibodies are Humaneered monoclonal antibodies. lenzilumab is used as a therapeutic for chronic myelomonocytic leukemia; for the prevention of acute graft versus host disease; and as a prophylactic companion for certain chimeric antigen receptor therapy (CAR-T) programs. The Company has developed or in-licensed targets or research antibodies, typically from academic institutions, and then applied its Humaneered technology to optimize them.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202312/31/2022YesYesYes--

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer, Acting Chief Financial Officer CameronDurrant 62 10/24/2022 1/11/2016
Chief Scientific Officer, Director Dale M.Chappell 52 2/5/2021 6/1/2016
Independent Director RonaldBarliant 77 1/11/2016 1/11/2016
Independent Director Rainer J.Boehm 63 2/1/2018 2/1/2018

Business Names
Business Name
Humanigen Australia Pty, Ltd.
Humanigen Europe, Ltd.
Humanigen, Ltd.
KaloBios, Ltd.

General Information
Outstanding Shares: 119,080,135 (As of 5/3/2023)
Shareholders: 31
Stock Exchange: OTC
Federal Tax Id: 770557236
Fax Number: (302) 531-3150


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024